USP 2040 Disintegration Dissolution

USP <2040> is the dietary-supplement-specific compendial chapter that adapts the well-established pharmaceutical disintegration (<701>) and dissolution (<711>) methods to the practical realities of supplement dosage forms: multi-ingredient blends, botanical matrices without a single marker, hard-shell two-piece capsules, softgels, chewables, and modified-release products. It tells you (a) whether disintegration alone is acceptable, (b) when dissolution is required, (c) which apparatus + medium to use, and (d) what stage-wise acceptance criteria (S1, S2, S3) apply.

Disintegration is performed in a USP <701> basket-rack apparatus: 6 tablets / capsules in 6 tubes, fluid-filled vessel at 37°C ± 2°C, vertical reciprocating motion 29 – 32 cycles/min. Dissolution is performed in a USP <711> apparatus: Apparatus 1 (basket, 100 rpm typical), Apparatus 2 (paddle, 50 – 75 rpm typical), or Apparatus 3 / 4 for specialised cases. Medium choice for supplements:

• Water — adequate for many immediate-release tablets; first-choice medium per <2040> when adequate.
• 0.1 N HCl (simulated gastric, SGF) — for ingredients requiring acid for solubility (calcium carbonate, iron) or for enteric-coat acid-resistance challenge.
• Phosphate buffer pH 6.8 (simulated intestinal, SIF) — for buffer-stage release of enteric products.
• Surfactant addition (0.1 – 1.0% SLS or polysorbate 80) — for poorly soluble fat-soluble nutrients (vitamin D, vitamin E, CoQ10) where a non-physiological surfactant is justified to achieve sink conditions.
• Acetate buffer pH 4.5 — for mid-pH solubility cases.

Both disintegration and dissolution use stage-wise acceptance, mirroring USP <711>. The product passes at S1 if all units meet the criterion; otherwise additional units are tested at S2; if still not met, at S3. This statistical-safety design protects both manufacturer and consumer against single-tablet stochastic failure.

• Multi-ingredient blends — no single marker captures the dissolution of the whole product; you must (a) select a representative marker, (b) test each clinically-relevant marker separately, or (c) use a non-specific assay (e.g. total polyphenols) where regulatorily defensible.
• Botanical matrices — solubility varies by extract solvent and harvest lot; the same SOP can produce different dissolution profiles on different lots; method must be robust enough to discriminate manufacturing issues from inherent matrix variability.
• Fat-soluble vitamins (A, D, E, K, CoQ10) — sink conditions require surfactant; surfactant choice must be justified and validated, not adopted from a similar drug product.
• Calcium carbonate / iron — pH-dependent solubility; SGF medium is mandatory; without it, the product looks like it disintegrates but doesn't dissolve at biological pH.
• Probiotic capsules — viable count is the assay, not chemistry; rupture-resistance test in acid (2 h) followed by release test in buffer; CFU recovery measured at end of buffer stage.
• Softgels with hydrophobic fills (fish oil, MCT, CoQ10) — gel-shell rupture is the meaningful endpoint; dissolution of the fill phase is not typically tested.
• Gummies + chewables — disintegration is largely inapplicable; the product is chewed; the appropriate quality attribute is dose uniformity and physical integrity, not in-vitro dissolution.

• No <2040>-grounded spec on the certificate of analysis — Warning Letter cite for failure to set finished-product spec per §111.70(e).
• Spec set with apparatus / medium not justified for the dosage form (e.g. paddle 50 RPM in water for an enteric tablet, which has no acid challenge).
• Q value tied to assay rather than label, masking the consumer's actual exposure.
• Stability programme tests assay only; disintegration tested at t=0 only; tablets harden over time and fail at release.
• Method development on R&D bench, never re-validated on the QC dissolution bath actually used for release — equipment-specific differences cause OOS.
• Sink-condition surfactant added 'for convenience' without justification — Warning Letter / 483 cite for non-physiological method.
• Probiotic enteric product tested in buffer only (skipping acid stage) — the enteric integrity is never challenged.

• Method master per dosage form: apparatus, medium, RPM, sampling time-points, acceptance stage table; version-controlled and change-controlled per §111.70.
• Validation linkage — method validation per <1225> attached as a controlled record; re-validation triggered on apparatus change, medium supplier change, or stability signal.
• LIMS test workflow — instrument-fed where supported (auto-sampling dissolution baths), manual entry otherwise; per-vessel result captured; S1 / S2 / S3 stage logic applied automatically.
• Stage-wise re-test gate — S1 fail does not auto-OOS; LIMS prompts S2 expansion under analyst e-sig; S3 expansion needs supervisor e-sig; final OOS only after S3 fail.
• Stability integration — every stability pull triggers a <2040> test at the protocol-defined time-points; trend chart on the stability dashboard.
• OOS workflow — fail at any stage triggers OOS investigation (analyst error vs method robustness vs product); CAPA linkage; batch-disposition gate.
• Spec sheet generation — finished-product spec includes <2040> spec verbatim; printed CoA cites <2040> and stage outcome.